JS207

Phase 2Small molecule

SShanghai Junshi Bioscience Co., Ltd.

JS207 is one of 337 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

336

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaRecruiting

Lung CancerNot yet recruiting

Triple-Negative Breast CancerRecruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerRecruiting

Colorectal CancerRecruiting

Hepatocellular CarcinomaRecruiting

Advanced Solid TumorsRecruiting

NSCLCActive, not recruiting

Advanced Malignant Solid TumorsNot yet recruiting

Nasopharyngeal CarcinomaPhase 2

Recruiting

Lung CancerPhase 2

Not yet recruiting

Triple-Negative Breast CancerPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Recruiting

Colorectal CancerPhase 2

Recruiting

Hepatocellular CarcinomaPhase 2

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

NSCLCPhase 2

Active, not recruiting

Advanced Malignant Solid TumorsPhase 2

Not yet recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

JS207

SShanghai Junshi Bioscience Co., Ltd.

Phase 2

1 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Duragesic

CCephalon

Preclinical

1 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Malignant Tumor

NCT06022250

Q1 2027

Phase 2Recruiting

Colorectal Cancer

NCT06885385

Q2 2027

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT06868836

Phase 1Active, not recruiting

Advanced Malignant Solid Tumors

NCT06571422

Q4 2027

Phase 2Active, not recruiting

NSCLC

NCT06944470

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT06868836·42 enrolled

JS207 (PD-1/VEGF Dual Antibody) Combined With Chemotherapy in First-line Treatment of Advanced Non-small Cell Lung Cancer

Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT06969027·69 enrolled

Advanced Malignant Solid Tumors2 trials

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Not yet recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT07480733·480 enrolled

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ47156 Monotherapy and in Combination With Other Anti-Tumor Therapies in Patients With Advanced Malignant Solid Tumors

Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT06571422·59 enrolled

Hepatocellular Carcinoma2 trials

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT06954467·72 enrolled

A Phase III, Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of JS207 in Combination With JS007 Versus Toripalimab in Combination With Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma

Not yet recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT07823348·560 enrolled

Advanced Solid Tumors1 trial

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 1/2·NCT07466160·280 enrolled

Colorectal Cancer1 trial

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT06885385·60 enrolled

7 more indications

Lung Cancer1 trial

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Not yet recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT07309276·864 enrolled

Triple-Negative Breast Cancer1 trial

JS207 Combination Therapy in Triple-negative Breast Cancer

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT07045311·80 enrolled

Breast Cancer1 trial

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

Advanced NSCLC1 trial

A Phase II Study of JS207 (PD-1/VEGF Dual Antibody) in Combination With or Without JS004 or Docetaxel in Advanced Non-small Cell Lung Cancer With Disease Progression During or After the Treatment of Platinum-based Chemotherapy and Immunotherapy

Terminated·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT06924606·18 enrolled

NSCLC1 trial

JS207 (Anti-PD-1/VEGF Bispecific Antibody) Combined With Platinum-based Doublet Chemotherapy in Subjects With Stage II-III Non-small Cell Lung Cancer

Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT06944470·78 enrolled

Nasopharyngeal Carcinoma1 trial

Phase I-II Study of JS207 a Bispecific Antibody Against PD1-VEGF in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting·CChinese University of Hong Kong·Phase 2·NCT07690787·49 enrolled

Malignant Tumor1 trial

A Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT06022250·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for JS207. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JS207 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JS207. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Junshi Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Junshi Bioscience Co., Ltd.

JS207

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q4 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Advanced Malignant Solid Tumors2 trials

Hepatocellular Carcinoma2 trials

Advanced Solid Tumors1 trial

Colorectal Cancer1 trial

Lung Cancer1 trial

Triple-Negative Breast Cancer1 trial

Breast Cancer1 trial

Advanced NSCLC1 trial

NSCLC1 trial

Nasopharyngeal Carcinoma1 trial

Malignant Tumor1 trial

References

Drug Info

Quick Facts

Related News